Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA – Get Free Report) dropped 5.7% during mid-day trading on Thursday . The company traded as low as $11.38 and last traded at $11.43. Approximately 174,001 shares traded hands during trading, a decline of 71% from the average daily volume of 608,047 shares. The stock had previously closed at $12.12.
Wall Street Analysts Forecast Growth
NMRA has been the topic of several research analyst reports. Mizuho began coverage on Neumora Therapeutics in a research note on Monday, July 8th. They set an “outperform” rating and a $20.00 price target on the stock. Needham & Company LLC reiterated a “buy” rating and set a $23.00 target price on shares of Neumora Therapeutics in a research report on Wednesday, August 7th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $22.33.
View Our Latest Stock Report on Neumora Therapeutics
Neumora Therapeutics Price Performance
Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported ($0.37) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.37). As a group, equities analysts anticipate that Neumora Therapeutics, Inc. will post -1.46 EPS for the current year.
Hedge Funds Weigh In On Neumora Therapeutics
Institutional investors have recently modified their holdings of the company. Avidity Partners Management LP grew its position in shares of Neumora Therapeutics by 10.6% during the fourth quarter. Avidity Partners Management LP now owns 1,990,632 shares of the company’s stock worth $33,940,000 after acquiring an additional 190,632 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Neumora Therapeutics during the first quarter worth about $10,354,000. SG Americas Securities LLC bought a new position in shares of Neumora Therapeutics during the second quarter worth about $566,000. New York State Common Retirement Fund bought a new position in shares of Neumora Therapeutics during the fourth quarter worth about $118,000. Finally, Amalgamated Bank bought a new position in shares of Neumora Therapeutics during the fourth quarter worth about $29,000. Institutional investors own 47.65% of the company’s stock.
Neumora Therapeutics Company Profile
Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.
Recommended Stories
- Five stocks we like better than Neumora Therapeutics
- 3 Tickers Leading a Meme Stock Revival
- CAVA Stock Rallies as Earnings Confirm It’s a Top Growth Play
- Most Volatile Stocks, What Investors Need to Know
- 3 High Short-Interest Stocks Poised for a Rate Cut Squeeze
- What Are the FAANG Stocks and Are They Good Investments?
- MarketBeat Week in Review – 8/19 – 8/23
Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.